Exjade (deferasirox), breakthrough once-daily oral iron chelator, available in Korea

Published: 2007-04-19 06:56:00

Updated: 2007-04-19 06:56:00

Exjade (deferasirox) is the first and only once-daily oral iron chelator for the treatment of iron overload in patients needing frequent blood transfusions for genetic blood disorders such as thalassaemia, sickle cell disease and other rare anaemias, according to a foreign honorable professor in ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK